Jefferies Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $14
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Jefferies analyst Kelly Shi maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $18 to $14.
Jefferies analyst Kelly Shi maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $18 to $14.